Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants

By Dr. Matthew Watson

WOBURN, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced successful field testing of prototype lines of the oilseed Camelina sativa that have been programed to produce PHA bioplastics directly in seed.

Read more:
Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants

Related Post

• Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant... - April 19th, 2024
• Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces... - April 19th, 2024
• Sanara MedTech Inc. Announces $55 Million Debt Facility - April 19th, 2024
• Pharming Group announces the placement of €100 million convertible bonds due 2029 - April 19th, 2024
• Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation - April 19th, 2024
• Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00 - April 19th, 2024
• Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States - April 19th, 2024
• Immix Biopharma on Track to Dose NXC-201 Patients in United States - April 19th, 2024
• Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - April 19th, 2024
• PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine - April 19th, 2024
• ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET - April 19th, 2024
• NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s &... - April 19th, 2024
• Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - April 19th, 2024
• Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted... - April 19th, 2024
• Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - April 19th, 2024
• Codexis to Report First Quarter 2024 Financial Results on May 2 - April 19th, 2024
• Addex to Present at the Swiss Biotech Day 2024 - April 19th, 2024
• Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - April 19th, 2024
• Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - April 19th, 2024
• FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer - April 19th, 2024
• Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B... - April 10th, 2024
• Ultimovacs – Invitation to Business Update on April 17, 2024 - April 10th, 2024
• Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective... - April 10th, 2024
• Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - April 10th, 2024
• Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 - April 10th, 2024
• Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today - April 10th, 2024
• ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 - April 10th, 2024
• Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - April 10th, 2024
• SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious... - April 10th, 2024
• Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results - April 10th, 2024
• Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference - April 10th, 2024
• Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2... - April 10th, 2024
• Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting - April 10th, 2024
• IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 - April 10th, 2024
• Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300... - April 10th, 2024
• Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual... - April 10th, 2024
• Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting - April 10th, 2024
• Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 - April 10th, 2024
• ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients... - April 10th, 2024
• Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024 - April 10th, 2024
• AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal... - March 26th, 2024
• Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - March 26th, 2024
• Gedeon Richter Selects Trial Interactive for Clinical Trial Management - March 26th, 2024
• Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of... - March 26th, 2024
• OXURION announces its presence at the Paris SmallCap event on March 28, 2024. - March 26th, 2024
• Foreløbige tal for 2023 og finansielle forventninger til 2024 - March 26th, 2024
• eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 26th, 2024
• Praxis Precision Medicines to Host PRAX-628 Program Update - March 26th, 2024
• BioCryst to Present at Upcoming Investor Conferences - March 26th, 2024
• NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference - March 26th, 2024
• Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results - March 26th, 2024
• QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system - March 26th, 2024
• Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights - March 26th, 2024
• Agile Therapeutics Announces Delisting from Nasdaq - March 26th, 2024
• Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones - March 26th, 2024
• United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA... - March 26th, 2024
• Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection - March 26th, 2024
• CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion - March 26th, 2024
• argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia - March 26th, 2024
• Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - March 26th, 2024
• Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024
• Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results - March 18th, 2024
• Nuvectis Pharma to Present at the 36th Annual Roth Conference - March 18th, 2024
• New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - March 18th, 2024
• Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million - March 18th, 2024
• Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - March 18th, 2024
• AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity - March 18th, 2024
• Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - March 18th, 2024
• Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - March 18th, 2024
• Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement... - March 18th, 2024
• Sanofi: Information concerning the total number of voting rights and shares - February 2024 - March 18th, 2024
• Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - March 18th, 2024
• Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - March 18th, 2024
• XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - March 18th, 2024
• Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - March 18th, 2024
• NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence - March 18th, 2024
• Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - March 18th, 2024
• Financière de Tubize - Annual report 2023 - March 18th, 2024
• Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - March 18th, 2024
• Idorsia and Viatris successfully close the transaction for the global research and development collaboration - March 18th, 2024

Global News Feed Comments Off on Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants | January 19th, 2021

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,960)
• Cardiac Stem Cells (1,250)
• Global News Feed (2,895)
• Integrative Medicine (105)
• IPS Cell Therapy (458)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,179)
• Spinal Cord Stem Cells (954)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy